Abstracts Archive - Page 1525 of 2607 - ACR Meeting Abstracts

Abstract Number: 2066 • 2017 ACR/ARHP Annual Meeting
Mediation Analysis to Understand Genetic Relationships between Habitual Coffee Intake and Gout
Joseph Hutton¹, Tanya Major², Ruth Topless³, Tony R. Merriman⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Biochemistry, University of Otago, Dunedin, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased coffee intake is associated with reduced serum urate concentrations and lower risk of gout. Recent genome wide association studies (GWAS) have shown that…
Abstract Number: 2067 • 2017 ACR/ARHP Annual Meeting
Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
Hyon K. Choi¹, Richard Johnson², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Medicine, University of Colorado Denver, Aurora, CO, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: There are significant correlations between serum uric acid (sUA) and blood pressure (BP) in individuals with and without gout.1 Limited data suggest that lowering…
Abstract Number: 2068 • 2017 ACR/ARHP Annual Meeting
Previous Prescription of Allopurinol Reduces the Risk of Nsaids-Related Acute Kidney Injury in Patients with Gout
Fernando Perez-Ruiz¹ and Sandra Chinchilla², ¹BioCruces Health Research Institute, Barakaldo, Spain, ²Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: untreated or undertreated gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with…
Abstract Number: 2069 • 2017 ACR/ARHP Annual Meeting
Gout Is More Frequent in Sickle Cell Disease Than the General Population
Richard Akintayo¹, Olufemi Adelowo², Adindu Chijioke¹, Timothy Olanrewaju¹, Kehinde Olufemi-Aworinde³ and Foluke Akintayo⁴, ¹Internal Medicine, University of Ilorin Teaching Hospital, Ilorin, Nigeria, ²Arthrimed Specialist Clinic:The Arthritis Centre, Lagos, Nigeria, ³Haematology, Bowen University Teaching Hospital, Ogbomosho, Nigeria, ⁴Family Medicine, Ladoke Akintola University of Technology Teaching Hospital, Ogbomosho, Nigeria
Background/Purpose: Despite the well known risk of hyperuricaemia in Sickle Cell Disease (SCD), it has not been determined if these patients are more prone to…
Abstract Number: 2070 • 2017 ACR/ARHP Annual Meeting
Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Naomi Schlesinger¹, Puja Khanna², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: A Delphi exercise reached consensus on a definition for gout remission that included serum uric acid (sUA) <6 mg/dL, no flares, resolution of all…
Abstract Number: 2071 • 2017 ACR/ARHP Annual Meeting
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Johji Nomura¹, Yoshimasa Takahashi², Kumiko Aoki², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: Hyperuricemia, abnormally elevated level of serum uric acid, is associated with gout as well as other diseases including metabolic syndrome, hypertension, diabetic kidney disease.…
Abstract Number: 2072 • 2017 ACR/ARHP Annual Meeting
A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Hyun A Lee¹, Sang-In Park¹, Seonghae Yoon², Makoto Onohara³, Jeongeun Choi⁴, Kyung-Sang Yu¹ and Howard Lee¹, ¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ²Clinical Trials Center, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. In…
Abstract Number: 2073 • 2017 ACR/ARHP Annual Meeting
Predictors for Clinically Diagnosed Gout – Results from 30 Years Follow-up of the Malmö Preventive Project Cohort in Southern Sweden
Meliha C. Kapetanovic¹, Peter M Nilsson², Carl Turesson³, Nicola Dalbeth⁴, Martin Englund⁵, Lieke E.J.M. Scheepers⁶ and Lennart TH Jacobsson⁶, ¹Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clinical Sciences, Lund University, Skåne University Hospital Malmö, Sweden., Lund, Sweden, ³Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁴University of Auckland, Auckland, New Zealand, ⁵Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is the most common form of arthritis worldwide. Hyperuricemia is a crucial risk factor resulting in accumulation of uric acid (s-UA) crystals in…
Abstract Number: 2074 • 2017 ACR/ARHP Annual Meeting
A Series of Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Studies to Evaluate the Efficacy, Safety, and Dose-Response Relationship of Orally Administered URC102, a Novel URAT1 Inhibitor, in Korean Patients with Gout
Jae-Bum Jun¹, Howard Lee², Chang-Hee Suh³, Chang Keun Lee⁴, Dong Wook Kim⁵, Jung-Yoon Choe⁶, Sang-Heon Lee⁷, Sang-Hyon Kim⁸, Seung-Jae Hong⁹, So-Young Bang¹⁰, Sung Jae Choi¹¹, Yong-Beom Park¹², Makoto Onohara¹³, Jeongeun Choi¹⁴, Jung Soo Song¹⁵ and Won Park¹⁶, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea, Republic of (South), ⁶Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of (South), ⁷Division of Rheumatology, Department of Internal Medicine,, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁸Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea, Daegu, Korea, Republic of (South), ⁹Department of Rheumatology, Kyung Hee University Medical Center, Seoul, Korea, Republic of (South), ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹¹Internal Medicine, Korea University Medical Center, Seoul, Korea, Republic of (South), ¹²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ¹³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ¹⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South), ¹⁵Rheumatology, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ¹⁶Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South)
Background/Purpose: URC102 is a novel URAT1 inhibitor under clinical development for the treatment of hyperuricemia with gout. A series of double-blind, placebo-controlled, randomized, multicenter, phase…
Abstract Number: 2075 • 2017 ACR/ARHP Annual Meeting
The Effect of Uric Acid Lowering Treatment on the Microbiome in Gout Patients
Hye Won Kim¹, Eun-Jeong Yoon², Seok Hoon Jeong² and Min-Chan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine,Gangnam Severance Hospital, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Severance Hospital, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Accumulating evidence indicates that gut microbiota interact with gout but it is still unknown how the uric acid lowering treatment (ULT) affects to the…
Abstract Number: 2076 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Allopurinol Versus Febuxostat in Preventing Incident Dementia in the Elderly
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Previous studies of hyperuricemia and dementia have provided contradictory findings, ranging from reduced to increased risk. Our objective was to assess the comparative effectiveness…
Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Sarah Keller¹, Sharan K. Rai², Na Lu¹, Amar Oza³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 2079 • 2017 ACR/ARHP Annual Meeting
Rotator Cuff Calcific Tendinopathy: Chondrocyte-like Cells Surrounding Calcific Deposits Express TNAP and ENPP1, Two Key Enzymes of the Mineralization Process.
Christelle Darrieutort-Laffite^1,2, Aurélie Najm^1,3, Thomas Garraud^1,2, Pierre Layrolle², Frédéric Blanchard³ and Benoit Le Goff^1,2, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²INSERM U1238, PHY-OS Laboratory, Nantes, France, ³INSERM U1238 University of medicine, PHY-OS Laboratory, Nantes, France
Background/Purpose: Calcific tendinopathy represents 10 to 42% of chronic painful shoulders. These calcium deposits are composed of carbonated apatite. Although the disease is frequent, its…
Abstract Number: 2080 • 2017 ACR/ARHP Annual Meeting
Serum Uric Acid and Incident Dementia: A Population Based Study
Lieke E.J.M. Scheepers¹, Mats Dehlin¹, Lennart TH Jacobsson¹, Lena Johansson² and Ingmar Skoog², ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Elevated serum uric acid (sUA) is an established risk factor for gout. Its role in the development of dementia is controversial, low levels of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].